스킵네비게이션

본문 바로가기 주메뉴 메인메뉴 국립장애인도서관홈페이지 바로가기

닫기

보존용자료이용 안내

닫기

책표지

검색히스토리

닫기

검색히스토리

* 보유한도 건수는 10건입니다.
검색히스토리 목록
자료구분 검색질의어 검색건수
     

상세검색

상세검색 닫기
자료구분 선택
단행자료
연속자료
멀티미디어자료
장애인자료
웹정보자료
선택된 자료구분
  • 자료구분 선택
도서 상세 검색
도서 상세 검색
분류기호 참조
청구기호 검색
한국대학명
코드명
대학명 참조
한국정부기관명
코드명
정부기관명 참조
도서 상세 검색
발행년도 년 부터
소장기관 검색
판종유형/판종
내용형식
KDC 주제
주제명을 이용한 검색

주제명을 통해 자료를 검색할 수 있습니다.

1. 주제를 입력하세요

주제명찾기
주제어 찾기

이용안내

검색방식 안내. 전방일치: 입력하신 키워드로 시작하는 주제어, 후방일치:입력하신 키워드로 끝나는 주제어, 부분일치:입력하신 키워드 포함하는 주제어

  • ① 검색방식
    • 전방일치- 입력하신 키워드로 시작하는 주제어
    • 후방일치- 입력하신 키워드로 끝나는 주제어
    • 부분일치- 입력하신 키워드 포함하는 주제어
  • ② 주제 입력란에 검색어를 입력하시고 [주제어 찾기]버튼을 클릭합니다.

2. 주제어를 선택하세요

목록

3. 주제어를 모아 검색할 수 있습니다.

선택된 주제명

[검색결과: 0건] 주제명을 선택하세요

학술기사

Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus

표제/저자사항
Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus / Seungbin Cha, Sun Hwa Lee, Sung Hun Kang, Mohammad Nazmul Hasan, Young Jun Kim, Sungpil Cho, Yong-kyu Lee
형태사항
p. 183-194 ; 30cm
주기사항
수록자료: Biomaterials research : the official journal of the Korean Society for Biomaterials. Korean Society for Biomaterials. Vol.22 no.3(2018 September), p. 183-194 22:3<183 ISSN 1226-4601↔
저자: Seungbin Cha, Department of Biomedical Chemistry, Konkuk University
저자: Sun Hwa Lee, KB-Biomed
저자: Sung Hun Kang, KB-Biomed
저자: Mohammad Nazmul Hasan, Department of Chemical and Biological Engineering, Korea National University of Transportation
저자: Young Jun Kim, Department of Biomedical Chemistry, Konkuk University
저자: Sungpil Cho, 4D Biomaterials Center, Korea National University of Transportation
저자: Yong-kyu Lee, KB-Biomed ; Department of Chemical and Biological Engineering, Korea National University of Transportation ; 4D Biomaterials Center, Korea National University of Transportation
수록잡지명
Biomaterials research : the official journal of the Korean Society for Biomaterials.
청구기호
662.6205-K84-22(3)
자료이용하는곳
3층 연속간행물실(서고자료대출반납)(보존)
자료 이용 방법
학술기사선택 => 바구니넣기 => 자료당일신청 후 [3층 연속간행물실(서고자료대출반납)(보존)] 에서 이용하십시오

초록내용/해제내용

인쇄

 Background: Diabetes mellitus (DM) is a chronic progressive metabolic disease that involves uncontrolled elevation of blood glucose levels. Among various therapeutic approaches, GLP-1 prevents type 2 diabetes mellitus (T2DM) patients from experiencing hyperglycemic episodes. However, the short half-life (< 5 min) and rapid clearance of GLP-1 often limits its therapeutic use. Here, we developed an oral GLP-1 gene delivery system to achieve an extended antidiabetic effect.
  Methods: Human IgG1 (hIgG1)-Fc-Arg/pDNA complexes were prepared by an electrostatic complexation of the expression plasmid with various ratios of the positively modified Fc fragments of an antibody (hIgG1-Fc-Arg) having a targeting ability to FcRn receptor. The shape and size of the complexes were examined by atomic force and field emission electron microscope. The stability of the complexes was tested in simulated gastrointestinal pH and physiological serum condition. Cellular uptake, transport, and toxicity of the complexes were tested in the Caco-2 cells. Biodistribution and antidiabetic effect of the complexes were observed in either Balb/c mice or Lepdb/db mice.
  Results: A 50/1 ratio of the hIgG1-Fc-Arg/pDNA produced a complex structure having approximately 40 ~ 60 nm size and also demonstrated protection of pDNA in the complex from the physiological pH and serum conditions. Cellular uptake and transport of the complex were demonstrated in Caco-2 cells having FcRn receptor expression and forming the monolayer-polarized structure. The cellular toxicity of both delivery vehicle and the complex revealed their minimal toxicity comparable with nontoxicity of a commercial transfection reagent. Biodistribution of the complex showed the detectable distribution of the complex in the most parts of gastrointestinal tract due to ubiquitous expression of the FcRn receptors. An in vivo type 2 diabetes treatment study of oral administration of hIgG1-Fc-9Arg/pGLP-1 complexes showed absorption and expression in GI tract of either Balb/c mice or Lepdb/db mice.
  Conclusion: In this study, we developed an oral GLP-1 gene delivery system on the platform of cationic hIgG1-Fc-9Arg. Prolonged t1/2, less immunoactivity, and better bioactivities of hIgG-Fc-9Arg/pGLP-1 complexes appeared to be a promising approach to achieve potent treatment of type 2 diabetes treatment.

펼쳐보기

알림

닫기
바구니 담기가 완료 되었습니다.
‘바구니’로 이동 하시겠습니까?

퀵메뉴

  • 메일링서비스 신청
  • 협약도서관 안내
  • 사서에게물어보세요
  • 프로그램 다운로드
맨위로
  • 페이지 위로
  • 페이지 아래로